Category: clinical study retractions

7th retraction for heart researcher who faked patient records

1.coverAnna Ahimastos, a heart researcher who faked patient records, has notched her 7th retraction.

One more paper is expected to be retracted, according to a spokesperson from her former institution, the Baker IDI Heart & Diabetes Institute in Australia.

As with the other retractions, the 2005 paper in Hypertension — about how the hypertension drug ramipril may help alleviate cardiovascular disease — is being pulled after Ahimastos admitted to scientific misconduct. She asserts the data remain valid, and has not signed the retraction notice.

The Hypertension paper has been cited 63 times, according to Thomson Scientific’s Web of Knowledge. Here’s the retraction note in full (the language will be familiar to readers who have been following this case):

Continue reading 7th retraction for heart researcher who faked patient records

Authors lied about ethics approval for study on obesity, depression

cover (1)

Obesity has retracted a study that suggested overweight people may be less depressed than their slimmer counterparts in cultures where fat isn’t stigmatized, after realizing the authors lied about having ethical approval to conduct the research.

The authors claimed their research protocol had been approved by Norwegian and Bangladeshi ethical committees, but, according to the retraction note, part of the study “was conducted without the required approval of the university ethics board.” The journal’s managing editor told us that there is no evidence that there was harm to the study subjects.

Here’s more from the retraction note for “In Bangladesh, overweight individuals have fewer symptoms of depression than nonoverweight individuals:”

Continue reading Authors lied about ethics approval for study on obesity, depression

Five years after a retraction, company’s stock is up more than 500%

wntloggawntresearchwebny1Is ethical behavior good for business?

Five years ago this month, Swedish pharmaceutical company WntResearch immediately notified shareholders when authors retracted a 2009 Proceedings of the National Academy of Sciences (PNAS) paper on a potential cancer therapy that was key to the company’s business.

At the time, the company’s decision to disclose the retraction hurt its finances, as WntResearch delayed its planned initial public offering for three weeks. It also offered investors and shareholders the opportunity to withdraw their shares of WntResearch stock.

But, aside from one of the paper’s co-authors, “No one did that,” Nils Brünner, WntResearch’s CEO, told us. Since the company’s IPO on December 17, 2010, its stock price has increased from Continue reading Five years after a retraction, company’s stock is up more than 500%

Investigation into CT scan paper reveals plagiarism

Screen Shot 2015-12-01 at 10.02.20 AMA paper on the quality of computed tomography (CT) images of the human body didn’t stand up to a close examination. It’s been retracted after an investigation found that it plagiarized work from two publications and a poster by another researcher.

The text in the Journal of the Korean Physical Society paper was taken from work by Kenneth Weiss, a radiologist at the University of Miami, and Jane Weiss, CFO of the couple’s medical imaging company. According to emails that Jane Weiss forwarded to us, Kenneth Weiss brought the plagiarism to light after a PhD student pointed out the similarities between the JKPS paper and one of Weiss’s in the American Journal of Roentgenology. Weiss notified the AJR in January. They started an investigation into the matter, and alerted the JKPS.

The retraction note for “Measurement of image quality in CT images reconstructed with different kernels” provides more details about the investigation:

Continue reading Investigation into CT scan paper reveals plagiarism

Plagiarized figure hurts arthritis paper

Screen Shot 2015-12-03 at 10.49.37 AM

A paper on a way to inhibit arthritis has been retracted following an investigation confirming that it plagiarizes a figure from another paper on the same topic.

The paper, “Blockade of 11β-hydroxysteroid dehydrogenase type 1 enzyme inhibits experimental collagenase-induced osteoarthritis,” was published in Molecular Medicine Reports. A figure claims to show cartilage treated with a specific inhibitor:

Screen Shot 2015-12-03 at 12.06.56 PM

The retraction note tells us that the authors reproduced the figure from another paper in Inflammation — which describes a different inhibitor:

Continue reading Plagiarized figure hurts arthritis paper

Diederik Stapel now has 58 retractions

stapel_npcSocial psychologist Diederik Stapel has notched his 58th retraction, after admitting he fabricated data in yet another article.

He’s holding onto his 4th place spot on our leaderboard.

This latest retraction is for “Correction or comparison? The effects of prime awareness on social judgments,” published in the European Journal of Social Psychology. As usual for Stapel, this paper has been retracted because he fabricated data.

Here’s the note:

Continue reading Diederik Stapel now has 58 retractions

My life as a whistleblower: Q&A with Peter Wilmshurst

We’re presenting a Q&A session with Peter Wilmshurst, now a part-time consultant cardiologist who has spent decades embroiled in misconduct investigations as a whistleblower.

Dr-Peter-Wilmshurst-007
Peter Wilmshurst

Retraction Watch: A UK judge recently upheld two findings of dishonesty by the Medical Practitioners Tribunal Service against Andrew Dowson, director of headache services at King’s College Hospital and your former co-investigator. Were you pleased with the verdict? (Last week, Dowson also began a four-month suspension from practicing medicine in the UK.) 

Peter Wilmshurst: In part, because I was pleased that he was shown to be dishonest, because I knew that he was, which was why I reported him. But I wasn’t pleased in the sense that I don’t think the investigation dealt with all the issues involved in the Migraine Intervention with STARflex Technology (MIST) Trial.

RW: What additional issues did you hope to see addressed? Continue reading My life as a whistleblower: Q&A with Peter Wilmshurst

Publisher error removes industry conflicts in vaccine paper

Screen Shot 2015-12-01 at 3.39.02 PM

An article about the use of vaccines against pertussis — also known as whooping cough — didn’t include the fact that the author has received grants and consultancy fees from three pharmaceutical companies that help make or sell the vaccines.

The correction to “Pertussis in young infants: a severe vaccine-preventable disease,” published in Autopsy and Case Reports just a few months after the paper, cites a “desktop publishing error” that led to the following problems: Continue reading Publisher error removes industry conflicts in vaccine paper

Did a clinical trial proceed as planned? New project finds out

Ben Goldacre
Ben Goldacre

A new project does the relatively straightforward task of comparing reported outcomes from clinical trials to what the researchers said they planned to measure before the trial began. And what they’ve found is a bit sad, albeit not entirely surprising.

As part of The Compare Project, author and medical doctor Ben Goldacre and his team have so far evaluated 36 clinical trials published by the top five medical journals (New England Journal of Medicine, the Journal of the American Medical Association, The Lancet, Annals of Internal Medicine, and British Medical Journal). Many of those trials included “switched outcomes,” meaning the authors didn’t report something they said they would, or included additional outcomes in the published paper, with no explanation for the change.

Here are the latest results from the project, according to its website:

Continue reading Did a clinical trial proceed as planned? New project finds out

NEJM pulls letter by heart researcher who faked patient records

Screen Shot 2015-11-30 at 10.08.23 AMA heart researcher who fabricated patient records has notched retraction number six — this time, for a letter in the New England Journal of Medicine. She has two more retractions forthcoming.

The retraction comes at the request of Anna Ahimastos’s co-authors, following an investigation into her work by her former workplace, the Baker IDI Heart and Diabetes Institute. The investigation was not able to verify the data referenced in the letter, which includes a citation for a recently retracted JAMA paper.

The retraction note is similar to others for Ahimastos’s papers:

Continue reading NEJM pulls letter by heart researcher who faked patient records